Gold prices just lower; monthly gains on track
NEW HAVEN, Conn. - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), currently trading at $15.57 with a market capitalization of $23.14 million, announced Friday it has modified an agreement with its largest warrant holder, restructuring the exercise terms of approximately 300,000 warrants. The company has shown impressive momentum, with a 30.25% return over the past week.
Under the amended agreement, about one-third of the warrants (100,000) will be exercised with cash, while the remaining two-thirds (approximately 200,000) will be exercised in a cashless manner.
The restructuring will reduce the number of new shares added to Precipio’s outstanding shares from approximately 300,000 to between 130,000 and 150,000, depending on the share price at the time of exercise. The company will receive approximately $1.2 million in cash inflow, down from the $3.8 million it would have received under the original terms.
Precipio management plans to provide additional details about this transaction during its upcoming quarterly shareholder call, scheduled for around August 15, 2025.
The company focuses on cancer diagnostics with a mission to address cancer misdiagnoses through diagnostic products and services. Precipio develops technologies in its laboratory and commercializes them as proprietary products for the global laboratory community.
The information was disclosed in a press release statement from the company.
In other recent news, Precipio Inc. reported a significant 43% increase in revenue for the first quarter of 2025, reaching $4.9 million. The company also achieved a 92% year-over-year improvement in adjusted EBITDA, despite a 9.5% sequential revenue decline attributed to seasonal factors. Precipio’s gross margins improved notably from 27% to 43%, reflecting operational efficiency and strategic investments in equipment and personnel. Analysts noted these developments as positive indicators of the company’s financial health and potential for future growth. Furthermore, Precipio’s CEO highlighted a major Medicare reimbursement approval for next-generation sequencing tests, which is expected to boost revenue and cash flow by approximately $250,000 per quarter. The company also announced improvements in operating expenses, which decreased as a percentage of revenue. These developments underscore Precipio’s robust performance and strategic positioning within the molecular diagnostics market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.